ZORYVE ® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, ...

Throughout the year, we saw robust net product sales revenue growth, steady prescription growth, and strong market share ...

Max Homa opens up about joining the Free to Be Me campaign, sharing his personal health journey and encouraging others to seek proper care.

Why aren't we talking about it more?

Executives from Arcutis Biotherapeutics (NASDAQ:ARQT) outlined their commercial priorities for the ZORYVE franchise, ...

It’s one thing for poor form to ruin your performance in a tournament. Every pro has those moments on the course where things ...

Maintaining skincare for many is a daily routine, with different seasons affecting the severity of certain skin conditions.

Arcutis Biotherapeutics delivered a strong Q4 2025, with $127.5M in revenue and a GAAP EPS beat, driven by Zoryve's rapid ...

Mandelic acid for the scalp gently exfoliates, reduces dandruff and oil, unclogs follicles, and supports healthier hair ...

Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was ...